Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loc3CAR: B7-H3-CAR T Cells for Pediatric Primary CNS Tumors
NCT05835687Phase 1Active, not recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Apr 2023
- Primary completion
- Jun 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of b7-h3-car t cells in central nervous system tumor and diffuse midline glioma (DMG) (2 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoint: Maximum Tolerated Dose at 7 days. Started Apr 2023; status: active, not recruiting.
02
Drugs
b7-h3-car t cells
03
Conditions
central nervous system tumordiffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT05835687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05835687.